Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Alesiani

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Plos One|November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosisGiuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Cancer|March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practiceMarino Clavio, Elena Crisà, Maurizio Miglino, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 18, 2012
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma RegistryMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Plos One|November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosisGiuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Blood|June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelomaMassimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Cancer|March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practiceMarino Clavio, Elena Crisà, Maurizio Miglino, et al.
Pageof 3